Pancreatic polypeptide inhibits somatostatin secretion

Area of Science:

• Neuroendocrinology
• Cellular Biology
• Receptor Pharmacology

Background:

• Neuropeptide Y4 receptor (NPY4R) is activated by pancreatic polypeptide (PP).
• The expression and function of NPY4R in various tissues remain unclear.
• Understanding NPY4R cellular localization is crucial for elucidating its physiological roles.

Purpose of the Study:

• To identify the specific cell types expressing NPY4R.
• To investigate the functional consequences of NPY4R activation by PP.
• To determine the role of PP-NPY4R signaling in somatostatin secretion.

Main Methods:

• Immunohistochemistry to detect NPY4R expression in pancreatic islets, duodenum, hippocampus, and hypothalamus.
• In vitro studies using mouse embryonic hippocampal (mHippo E18) cells to assess somatostatin secretion.
• In vivo experiments involving central injection of PP in mice and subsequent c-Fos immunoreactivity analysis.

Main Results:

• NPY4R is expressed in all somatostatin-containing cells across tested tissues.
• PP activation of NPY4R significantly decreased somatostatin secretion from human islets and mHippo E18 cells.
• Central PP administration induced c-Fos expression in hippocampal somatostatin cells, indicating receptor activation.

Conclusions:

• Pancreatic polypeptide (PP) is identified as a key regulator of somatostatin secretion.
• NPY4R is confirmed as the primary receptor mediating PP's effects on somatostatin cells.
• These findings establish a novel signaling pathway involving PP and somatostatin in the brain and periphery.